The Adaptive Experience

The time from Clonality (ID) test to first Tracking (MRD) test is usually within 3 months for patients with ALL.

When is clonoSEQ being implemented for patients with ALL?

Initiation of clonoSEQ MRD testing will vary based on a patient’s presentation and treatment course.  For most ALL patients, the first Tracking (MRD) will be evaluated within 3 months of diagnosis*, and more than 85% of clonoSEQ-tested patients will have had their first MRD test within a year of diagnosis.

*Assumes ID collection date is indicative of time of diagnosis

AdaptiveExp 2

This page is intended for use by healthcare professionals of the United States.

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit